Caxton Associates LLP Arvinas, Inc. Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Arvinas, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 604,785 shares of ARVN stock, worth $6.39 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
604,785
Previous 298,062
102.91%
Holding current value
$6.39 Million
Previous $2.19 Billion
99.77%
% of portfolio
0.13%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding ARVN
# of Institutions
238Shares Held
65.2MCall Options Held
1.23MPut Options Held
372K-
Vanguard Group Inc Valley Forge, PA8.56MShares$90.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$66.2 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA5.58MShares$58.9 Million5.5% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.35MShares$35.4 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.13MShares$22.5 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $562M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...